ORIGINAL PAPER
Intestinal microbiota in nephrotic children treated with immunosuppressive agents
More details
Hide details
1
Department of Neonatology, Tomaszow Health Center, Tomaszow Mazowiecki, Poland
2
Department of Thoracic Surgery and Respiratory Rehabilitation, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
3
Department of Anesthesiology and Intensive Therapy, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
4
Department of Paediatrics, Immunology and Nephrology, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
5
Department of Obstetrics, Perinatology and Gynecology, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
6
Division of Didactics in Pediatrics, Medical University of Lodz, Lodz, Poland
Submission date: 2019-12-10
Final revision date: 2020-03-06
Acceptance date: 2020-03-10
Publication date: 2020-03-31
Pediatr Pol 2020;95(1):6-13
KEYWORDS
TOPICS
ABSTRACT
Aim of the study:
The analysis of the effect of immunosuppressive therapy on gut microbiota in pediatric patients with stable idiopathic nephrotic syndrome (INS) treated with different protocols of immunosuppressive therapy and examined the changes in their gut microbiota components along with accompanying clinical symptoms.
Material and methods:
The study consisted of 44 children with INS divided into 3 groups according to treatment protocols (group A: 18 children on cyclosporine A [CsA], 9 of which receiving additional glucocorticosteroids [GCS]; group B: 17 children on GCS; and group C: 9 children on cyclophosphamide [CYC] and GCS), along with 20 healthy children serving as controls. Intestinal microflora was analysed with microbiological diagnostics based on KyberStatus and KyberMyk tests. Additional laboratory blood and urine tests were performed along with history data and clinical symptoms analysis. Study was approved by local Ethical Committee. All caregivers gave an informed consent for participation.
Results:
Total number of bacterial colonies was significantly lower in group A (p < 0.001) and group B children (p = 0.04) when compared to the healthy controls. Group C children had a significantly lower number of Bifidobacterium colonies than the controls (p = 0.01), while number of Candida colonies were significantly higher in group A subjects than in controls (p = 0.01). No significant correlation between clinical symptoms reported by patients and the therapy used was found. Degree of disbiosis did was not related to the patients’ complaints either.
Conclusions:
Immunosuppressed INS paediatric patients who are in remission had significantly unfavourable changes in their intestinal microbiota. Patient on chronic CsA therapy showed higher degree of dysbiosis.
REFERENCES (23)
1.
Kinsman OS, Pitblado K. Candida Albicans gastrointestinal colonization and invasion in the mouse: Effect of antibacterial dosing, antifungal therapy and immunosuppression. Mycoses 1989; 32: 664-674.
2.
Borriello SP. The normal flora of the intestinal tract. In: Gut Ecology, Hart AL, Stagg AJ, Graffner H, et al. (eds.). Martin Dunitz Ltd., London 2002: 3-12.
3.
Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001; 291: 1115-1118.
4.
Hwang JS, Im CR, Im SH. Immune disorders and its correlation with gut microbiome. Immune Netw 2012; 12: 129-138.
5.
Wrong OM. Bacterial metabolism of protein and endogenous nitrogen compounds. In: Rowland IR eds. Role of gut flora in toxicity and cancer. Academic Press, New York 1988: 227-262.
6.
Kau AL, Ahern PP, Griffin NW, et al. Human nutrition, the gut microbiome, and immune system: envisioning the future. Nature 2011; 474: 327-336.
7.
Tsuji S, Suruda C, Hashiyada M, et al. Gut microbiota dysbiosis in children with relapsing idiopathic nephritic syndrome. Am J Nephrol 2018; 47: 164-170.
8.
Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A report of the International Study of Kidney Disease in Children. Kidney Int 1981; 20: 765-771.
9.
Enck P, Zimmermann K, Rusch K, et al. The effects of maturation on the colonic microflora in infancy and childhood. Gastroenterol Res Pract 2009; 2009: 752401.
10.
Si JM1, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10: 1802-1805.
11.
Sharma R, Young C, Mshvidobadze M, et al. Mikroflora jelit: czy ma znaczenie w chorobach u noworodków? [Intestinal microflora: is it important in neonatal diesease?]. Medycyna po Dyplomie 2010; 14: 70-86.
12.
Cunningham-Rundles S, Ahrne S, Bengmark S, et al. Probiotics and immune response. Am J Gastroenterol 2000; 95 (Suppl 1): S22-25.
13.
Isolauri E, Sutas Y, Kankaanpaa P, et al. Probiotics effects on immunity. Am J Clin Nutr 2001; 73: 444-450.
14.
Samonis G, Karyotakis NC, Anaissie EJ, et al. Effects of cyclophosphamide and ceftriaxone on gastrointestinal colonization of mice by Candida albicans. Antimicrob Agents and Chemother 1996; 40: 2221-2223.
15.
Koh AY, Köhler JR, Coggshall KT, et al. Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog 2008: 4: e35.
16.
Bowen JRC, Sahi S. Cyclosporine induced colitis. Br Med J 1993; 307: 484.
17.
Kaur S, Vaishnavi C, Ray P, et al. Effect of biotherapeutics on cyclosporine-induced Clostridium difficile infection in mice. J Gastroenterol Hepatol 2010; 25: 832-838.
18.
Bast A, Chandler RF, Choy PC, et al. Botanical health products, positioning and requirements for effective and safe use. Environ Toxicol Pharmacol 2002; 12: 195-211.
19.
Shenderov BA, Glukhova EV, Viadro MM. Microbial ecology of laboratory animals as a model in evaluation of the immunomodulating and antimicrobial agents. Antibiot Khimioter 1992; 37: 39-43.
20.
Morgan MY, Blei A, Grüngreiff K, et al. The treatment of hepatic encephalopathy. Metab Brain Dis 2007; 22: 389-405.
21.
Siew C, Plamondon S, Kamm MA, et al. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflam Bowel Dis 2010; 16: 1286-1298.
22.
Friend DR. Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 1998; 12: 591-603.
23.
Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004; 93: 97-108.